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Objective: To observe the anti-proliferation and radiosensitization effect of chitooligo-
saccharides (COS) on human lung cancer cell line HepG2.
Methods: CCK-8 assay was employed to obtain the inhibition ratio of COS on HepG2
cells at 24 h after treatment. The clonogenic assay was used to analyze the cell viability of
RAY group and RAY + COS group with X-ray of 0, 1, 2, 4, 6 and 8 Gy, and the cell
survival curve was used to analyze the sensitization ratio of COS. Flow cytometry was
employed to detect cell cycle and apoptosis rate in control group, RAY group and
RAY + COS group after 24 h treatment.
Results: COS inhibited the proliferation of HepG2 cells, and the inhibition rate posi-
tively correlated with the concentration of COS. The cell viability decreased with
increasing exposure dose in RAY group and RAY + COS group. The cell viabilities of
RAY + COS group were lower than those of RAY group at the dose of 4, 6 and 8 Gy
(P < 0.05), and the sensitization ratio of COS was 1.19. There were higher percentage at
G2/M phase and apoptosis rate, and lower percentage at S phase in RAY + COS group
versus the other two groups (P < 0.01).
Conclusions: COS can inhibit the proliferation of HepG2 cells, and enhance the radi-
osensitization of HepG2 cells, induce apoptosis and G2/M phase arrest.1. Introduction
Despite of the rapid development of modern medical tech-
nology, cancer is still the biggest challenge in medical ﬁeld,
posing immense threat on human's life and health. Bad habits
like smoking, together with worsening air pollution and indus-
trial fumes directly cause the surging population with lung
cancer [1,2]. Lung cancer has topped the list of cancer rate in
many developed countries and morbidity in major cities of
China, which urges the tough ﬁght against lung cancer [3–5].
Radiotherapy is one of the three weapons against lung cancer
and plays an immeasurably important role in the treatment of
lung cancer with over 70% patients [6–8]. However, attacking
wrong objects happens due to low capacity of radioactive raysto identify the pathological cells, thus, the top priority for
researchers is to efﬁciently eliminate the ‘invaders’ and
meanwhile protect the ‘peers’. Chitooligosaccharides (COS),
produced from chitin, becomes the focus because its
characteristics like easy solubility and high absorptivity are
apparently better than polymer sugar. Currently, few COS
reports focused on its application in radiosensitization of
cancer cell [9,10]. This research aims to investigate the
elevating sensibility of human lung cancer line HepG2 treated
with COS to radiotherapy, and to verify the auxiliary
synergism of COS on radiotherapy in order to explore the
therapy for cancer with better efﬁcacy and lower damage.
2. Materials and methods
2.1. Cell line and experimental materials
Human lung cancer line HepG2 was purchased from Institute
of Cell Biology, Chinese Academy of Sciences. Electron linear
accelerator was purchased from Nanjing Chuang Rui Yingopen access article under the CC BY-NC-ND
Table 1
Anti-proliferation effect of COS on HepG2.
COS quantity
(mg)
COS concentration
(mg/mL)
OD
(mean ± SD)
Inhibition
ratio (%)
0.000 0.0 1.024 ± 0.005 0.00
0.055 0.5 0.938 ± 0.006* 8.35
0.110 1.0 0.841 ± 0.006* 17.90
0.220 2.0 0.754 ± 0.008* 26.37
0.330 3.0 0.650 ± 0.005* 36.51
0.440 4.0 0.584 ± 0.007* 44.72
0.550 5.0 0.458 ± 0.006* 55.19
*P = 0.000 in comparison with COS of 0 mg.
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Shanghai GemTop Scientiﬁc Instrument Co., LTD. COS was
purchased from Shanghai Hui Cheng Biological Technology
Co., LTD. CCK-8 kit was purchased from Shanghai Li Rui
Biotechnology Co., LTD.
2.2. Experimental methods
Cell lines HepG2 of seven concentration levels were created
and HepG2 of each concentration was divided into 3 wells at the
same time to make parallel samples. The cell lines HepG2 were
cultured until the logarithmic phase. After digestion and dilution,
the concentration was made into 4 × 104/mL and according to
0.1 mL/well, HepG2 was put into 96-well board for attachment
culture in suitable environment. Twenty four hours later, the
fresh culture medium of 0.11 mL/well diluted with COS was
replaced and COS was added into each well with quantity of 0,
0.055, 0.11, 0.22, 0.33, 0.44, 0.55 mg. Twenty four hours after
COS inﬁltration, CCK-8 reagent was added along the wall at
0.01 mL/well. A little tapping was for the good mixture of re-
agent and culture solution. Four hours after the full reaction,
optical density (OD) in each group was determined at the wave
length of 450 nm. The procedure was repeated 3 times to
investigate the anti-proliferation effect of COS on HepG2 and
hereby COS with concentration of 1.0 mg/mL was taken for the
further research.
X ray of six exposure dose levels was created with RAY group
and RAY + COS group in each dose level and each group was
divided into 3 wells at the same time to make parallel samples.
According to 200/well for exposure dose of 0, 1, 2 Gy, 400/well
for 4, 6 Gy and 800/well for 8 Gy, X ray was inoculated on 6-well
culture plate and single-cell suspension of different concentra-
tions was added to it for attachment culture in the incubator in
suitable condition. Six hours later, COS of certain quantity was
added to each well in RAY + COS group to make the concen-
tration of 1.0 mg/mL. Culture medium of the equivalent quantity
was added to each well in RAY group for 24 h inﬁltration. The
tissue analog of about 1 cm was capped on the culture plates in
both groups and exposed to 6MvX ray, at the distance of 100 cm
and dose rate of 2 Gy/min. The culture was continued for 10 d.
After rinsing, fastening and staining, the number of cell cluster
combined of more than 50 units was counted. The procedure was
repeated 3 times to collect data and draw up the cell survival curve
so that the sensitization enhancement ratio can be calculated by
formula sensitization enhancement ratio = Do (RAY)/Do
(RAY + COS), where DO was the ﬁnal slope.
Three groups were created and each group was divided into 3
wells tomake parallel samples. Cell suspension of 1 × 105/mLwas
inoculated into 6-well culture plate for attachment culture in the
suitable environment for 24 h. Certain COS was added to
RAY + COS group to make the concentration of 1.0 mg/mL.
Culturemediumof equivalent quantitywas added to control group
and RAY group. RAY group and RAY + COS group were
exposed to 4 Gy X ray after 24 h inﬁltration. The culture was
continued for 24 h after changing the fresh culture medium. After
digestion, rinsing, dilution and other operation, the cell cycle and
apoptosis rate were determined.
2.3. Statistical methods
SPSS17.0 software was used for statistical analysis. Mea-
surement data were expressed by mean value ± standarddeviation (mean ± SD) and t test was applied. If P < 0.05, the
differences were considered statistically signiﬁcant.
3. Results
3.1. Anti-proliferation effect of COS on HepG2
Compared with the OD value without addition of COS, the
other OD values were decreased with the increasing COS con-
centrations and the differences were statistically signiﬁcant
(P < 0.01), which suggested that the amount of living cells was
decreased with increasing COS quantity, the proliferation of
HepG2 inﬁltrated with COS was inhibited and that the inhibition
ratio and COS concentration was positively correlated. Detailed
information was in Table 1.
3.2. Comparison of cell survival rates
Compared with the exposure dose of 0, the survival rates in
RAY group and RAY + COS group were gradually decreased
with increasing exposure dose and the decreasing range in
RAY + COS group was bigger. The survival rates in
RAY + COS group were slightly lower than in RAY group at
the exposure dose of 1, 2 Gy but the differences were not
statistically signiﬁcant (P > 0.05). When at the exposure dose
of 4, 6, and 8 Gy, the survival rates in information were lower
than in RAY group and the differences were statistically
signiﬁcant (P < 0.05). Detailed information was in Table 2.
The sensitization enhancement ratio of COS to HepG2 was
1.19.
3.3. Comparison of cell cycle distributions
Compared with control group, the percentages of cells at S
phase in RAY group and RAY + COS group were signiﬁcantly
lower while cells at G2/M phase were higher; and both differ-
ences were statistically signiﬁcant (P < 0.01). Cells at Go/G1
phase in RAY + COS group were relatively more and the dif-
ference was statistically signiﬁcant (P < 0.05). In contrast with
RAY group, cells at S phase in RAY + COS group took up
smaller percentage and cells at G2/M phase higher percentage,
with statistically signiﬁcant differences (P < 0.01). The differ-
ences in duration ratio at Go/G1 phase in both groups were not
statistically signiﬁcant (P > 0.05). Detailed information was in
Table 3.
The apoptosis rates in RAY group and RAY + COS group
were much higher than in control group and the differences were
statistically signiﬁcant (P < 0.01). The apoptosis rate in
Table 2
Comparison of cell survival rates in groups at different exposure doses.
Exposure rate (Gy) Cell survival rate (%)
RAY RAY + COS
0 99.17 ± 4.82 99.05 ± 3.23
1 92.73 ± 4.08 91.66 ± 3.72
2 74.87 ± 3.59 70.26 ± 2.35
4 42.33 ± 2.84 35.07 ± 3.32*
6 23.01 ± 2.77 16.82 ± 1.86*
8 5.64 ± 1.03 3.11 ± 1.15*
*P < 0.05 in comparison with RAY group.
Table 4
Comparison of cell apoptosis rate.
Groups Cell apoptosis rate (%);
Control group 2.17 ± 1.24
RAY group 17.47 ± 1.83*
RAY + COS group 24.81 ± 1.62*
*P = 0.000 in comparison with control group.
Table 3
Comparison of cell cycle distribution.
Groups S (%) G0/G1 (%) G2/M (%)
Control group 48.33 ± 1.88 46.02 ± 2.83 5.65 ± 1.82
RAY group 35.27 ± 1.49* 50.50 ± 3.07 14.23 ± 1.36*
RAY + COS
group
22.95 ± 1.54*△ 54.24 ± 2.76* 22.81 ± 1.56*△
*P < 0.05 in comparison with control group; △P < 0.01 in comparison
with RAY group.
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tistically signiﬁcant differences (P < 0.05). Detailed information
was in Table 4 and Figure 1.
4. Discussion
Heavy haze raised lung cancer incidence and the close
connection between PM2.5 and lung cancer has been conﬁrmed
by researchers all over the world [11–13]. The annual growth rateFigure 1. Comparison of cell apoptosis.of lung cancer incidence in China is astoundingly over 25% and
population that dies from lung cancer each year has increased to
4.5 times that of 1982 [14]. The present research aims to create a
combined medication of COS and radiotherapy by taking the
human lung cancer cell line HepG2 as the experimental object,
to enhance the radiotherapeutic effect and reduce adverse
effect so that to improve the life quality of cancer patients.
4.1. Direct anti-proliferation effect
The successful application of enzymolysis approach in the
1990s achieved the industrial production of COS [15]. That
natural low molecular sugar polymer is compatible with
human body and without adverse effect, has drawn the
attention of medical investigators for its various physiological
regulation functions [16–18]. The present research veriﬁes that
COS has the direct anti-proliferation effect on human lung
cancer cell line HepG2 and the inhibitory rate is synchronously
increased with the increasing COS quantity, which also veriﬁes
that COS expresses tumor-suppression activity against various
cell lines. Kim and Karagozlu et al reported the inhibitory and
killing effects of COS on leukemia HL-60 cell and gastric cancer
AGS cell respectively [19,20]. Fernandes also established models
to verify that COS inhibited the development of bladder
tumor [21].
4.2. Promoting apoptosis of cancer cells
Ever since X ray and radium were discovered and applied to
radiotherapy, radiotherapy has made great achievements in less
than 100 years and become one of the major methods against
cancer. Data revealed that the cure rate of cancers including
oropharyngeal, tonsillar, maxillary cancer by radiotherapy was
over 35% on average and early-stage cervical cancer even reached
86%–94%; radiotherapy was widely used before and after resec-
tion to shrink the tumor and eliminate the residue [22–24]. However,
the collateral damage of radioactive rays could cause normal
tissue, which is a huge burden and ordeal for patients. The
present research testiﬁes that RAY group and RAY + COS
group could encourage mass apoptosis of cancer cells and
RAY + COS group with stronger lethality is more efﬁcient at
the same exposure dose, which supports the theory that COS
can regulate the natural apoptosis of cancer cells from multi-
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normal cells, which is beneﬁcial for the organism to keep alive and
adapt to surroundings while cancer cells enter the abnormal
growth model due to the loss of apoptosis regulation. Researches
have demonstrated that COS can lower the expression of B-cell
lymphoma 2 to openmultiple pathways to stimulate apoptosis like
reducing the intracellular glutathione level and animating oxida-
tion, accelerating transmembrane transport of Ga2+, initiating
inducing apoptosis of relevant inhibitor TG, activating cyto-
chrome complex to shift from mitochondria to cytoplasm and
producing superoxide anion [25–27]. In addition, COS can also
elevate the Bax level, release Caspase and restrain synthesis of
ATP to stimulate apoptosis [28].
4.3. Changing cancer cell cycle distribution
The testing results of ﬂow cytometry indicated that compared
with control group, the duration at each stage of cell cycle in
RAY group and RAY + COS group was changing. And
RAY + COS group under the effect of COS had more signiﬁcant
chang in contrast with RAY group; S phase was relatively
shortened; Go/G1 and G2/M phases were relatively prolonged.
Cell cycle kinetics provides theoretical guidance for radio-
therapy; cells at M phase are the weakest with the lowest
threshold value of being killed; cells at G2 phase are the most
seriously injured after exposure to rays with retarding speed of
cell division; cells at S phase are the least affected by radiation
[29]. The combined therapy of COS inﬁltration and radiotherapy
can make cancer cells stay at G0/G1 and G2/M phases to a larger
extent and reduce the number of cells entering into S phase so
that to improve the therapeutic effect of radiotherapy.
In conclusion, COS not only plays the direct anti-
proliferation effect on HepG2 growth, but also promotes cells
apoptosis, leads to the changing of proliferation process and
efﬁciently improves the sensitivity of HepG2 to radioactive rays.
When COS is combined with radiotherapy, it can greatly
improve the therapeutic effect and meanwhile reduce the adverse
damage on patients caused by radiotherapy. As the ‘Jack of all
trades’ in medical ﬁeld, COS possesses tremendous potential in
clinical treatment.
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